Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
5800 participants
OBSERVATIONAL
2023-01-01
2033-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rare Embryonal Tumors of the Central Nervous System: International Registry
NCT05711992
Magnetic Resonance Imaging in Treating Children With Progressive Low-Grade Astrocytoma
NCT00005084
Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma
NCT00005082
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
NCT05025969
Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
NCT01106794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Data collected include demographics, disease characteristics, treatment information, radiological imaging, and biospecimen collection if available ( tumor tissues Patients will be followed longitudinally to obtain outcome data. Data collection will continue for approximately 10 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CNS Sarcoma
Patients diagnosed with Central nervous system (CNS) sarcomas
No interventions assigned to this group
BCOR-altered
Patients diagnosed with tumors characterized by alterations in the BCOR gene.
No interventions assigned to this group
Astroblastoma/MN-1- altered
Patients diagnosed with Astroblastomas/MN-1 alterations
No interventions assigned to this group
Unclassifiable tumors
Patients diagnosed with histologically ambiguous tumors or tumors that fail to classify with the current diagnostic methods.
No interventions assigned to this group
Other Rare Brain tumors
Patients diagnosed with other rare brain tumors that do not meet the criteria for cohorts 1-4.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a known or suspected BCOR-altered brain tumor
* Patients with a known or suspected Astroblastoma/NM-1 altered brain tumor
* Patients with known or suspected histologically ambiguous/unclassifiable brain tumor
* Patients with a known or suspected rare brain tumor.
* Signed informed consent by patient/ parent or guardian (assent where applicable) to participate in the study.
Exclusion Criteria
* The patient is older than 46 years of age at diagnosis.
* The patient or family is not willing to participate or does not sign informed consent.
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's National Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adriana Fonseca
Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nathan Robison
Los Angeles, California, United States
Marie Jaeger-Krause
San Francisco, California, United States
Children's National Hospital
Washington D.C., District of Columbia, United States
Scott Raskin
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00000324
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.